Back to news FoRx Therapeutics Announces Development Candidate Nomination of Potential Best-in-Class PARG Inhibitor FORX-428 FoRx Therapeutics’ PARG – Poly(ADP-ribose) glycohydrolase – inhibitor FORX-428, a potent and selective small molecule, was nominated as...
Back to news FoRx Therapeutics AG appoints Tarig Bashir as Chief Executive Officer Basel, Switzerland, 01 April, 2021 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the...
Back to news FoRx Therapeutics AG appoints Ulrich Lücking as Head of Chemistry Basel, Switzerland, 01 June, 2020 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the...
